A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
| Member | Definition | Class |
|---|
| 1,4-butanediol | A butanediol that is butane in which one hydrogen of each of the methyl groups is substituted by a hydroxy group. A colourless, water-miscible, viscous liquid at room temperature (m.p. 16degreeC) with a high boiling point (230degreeC), it is mainly used for the production of other organic chemicals, particularly the solvent oxolane (also known as tetrahydrofuran or THF). | butane-1,4-diol |
| 2-hydroxyestradiol | A 2-hydroxy steroid that consists of 17beta-estradiol having an additional hydroxy group at position 2. | 2-hydroxy-17beta-estradiol |
| 4-phenylbutyric acid | A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation. | 4-phenylbutyric acid |
| 4-phenylbutyric acid, sodium salt | The organic sodium salt of 4-phenylbutyric acid. A prodrug for phenylacetate, it is used to treat urea cycle disorders. | sodium phenylbutyrate |
| abiraterone acetate | A sterol ester obtained by formal condensation of the 3-hydroxy group of abiraterone with the carboxy group of acetic acid. A prodrug that is converted in vivo into abiraterone. Used for treatment of metastatic castrate-resistant prostate cancer. | abiraterone acetate |
| acemetacin | A carboxylic ester that is the carboxymethyl ester of indometacin. A non-steroidal anti-inflammatory drug, it is used in the treatment of rheumatoid arthritis, osteoarthritis, and low back pain, as well as for postoperative pain and inflammation. Its activity is due to both acemetacin and its major metabolite, indometacin. | acemetacin |
| adefovir dipivoxil | An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection. | adefovir pivoxil |
| amdinocillin pivoxil | A penicillanic acid ester that is the [(2,2-dimethylpropanoyl)oxy]methyl ester and prodrug of mecillinam. | pivmecillinam |
| amifostine anhydrous | An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy. | amifostine |
| aminolevulinic acid | The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp. | 5-aminolevulinic acid; 5-ammoniolevulinate |
| aminolevulinic acid hydrochloride | A hydrochloride that is the monohydrochloride of 5-aminolevulinic acid. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp. | 5-aminolevulinic acid hydrochloride |
| amodiaquine | A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position. | amodiaquine |
| ampiroxicam | A benzothiazine that is the 1-[(ethoxycarbonyl)oxy]ethyl ether of piroxicam. A prodrug for piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis. | ampiroxicam |
| amrubicin | A synthetic anthracycline antibiotic with molecular formula C25H25NO9. A specific inhibitor of topoisomerase II, it is used (particularly as the hydrochloride salt) in the treatment of cancer, especially lung cancer, where it is a prodrug for the active metabolite, ambrucinol. | amrubicin |
| ancitabine | An organic heterotricyclic compound resulting from the formal condensation of the oxo group of cytidine to the 2' position with loss of water to give the corresponding cyclic ether. A prodrug, it is metabolised to the antineoplastic agent cytarabine, so is used to maintain a more constant antineoplastic action. | ancitabine |
| aripiprazole lauroxil | A dodecanoate ester obtained by formal condensation of the carboxy group of dodecanoic acid with the hydroxy group of 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-2-oxo-3,4-dihydroquinolin-1(2H)-yl]methanol. A prodrug for aripiprazole, it is used for treatment of schizophrenia. | aripiprazole lauroxil |
| azaribine | A N-glycosyl-1,2,4-triazine that is 6-azauridine acetylated at positions 2', 3' and 5' on the sugar ring. It is a prodrug for 6-azauridine and is used for treatment of psoriasis. | azaribine |
| azathioprine | A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS. | azathioprine |
| azd 1152 | A dihydrogen phosphate prodrug of a pyrazoloquinazoline aurora kinase inhibitor AZD1152-hydroxyquinazoline pyrazol anilide(HQPA) and is converted rapidly to the active AZD1152-HQPA in plasma. | AZT-1152 |
| bacampicillin | A penicillanic acid ester that is the 1-ethoxycarbonyloxyethyl ester of ampicillin. It is a semi-synthetic, microbiologically inactive prodrug of ampicillin. | bacampicillin |
| baicalin | The glycosyloxyflavone which is the 7-O-glucuronide of baicalein. It is an active ingredient of Chinese herbal medicine Scutellaria baicalensis. | baicalin |
| bambuterol | A carbamate ester that is terbutaline in which both of the phenolic hydroxy groups have been protected as the corresponding N,N-dimethylcarbamates. A long acting beta-adrenoceptor agonist used in the treatment of asthma, it is a prodrug for terbutaline. | bambuterol |
| bambuterol hydrochloride | The hydrochloride salt of bambuterol. A long acting beta-adrenoceptor agonist used in the treatment of asthma, it is a prodrug for terbutaline. | bambuterol hydrochloride |
| beclomethasone dipropionate | A steroid ester comprising beclomethasone having propionyl groups at the 17- and 21-positions. | beclomethasone dipropionate |
| benazepril | A benzazepine that is benazeprilat in which the carboxy group of the 2-amino-4-phenylbutanoic acid moiety has been converted to the corresponding ethyl ester. It is used (generally as its hydrochloride salt) as a prodrug for the angiotensin-converting enzyme inhibitor benazeprilat in the treatment of hypertension and heart failure. | benazepril |
| benzoylmetronidazole | A benzoate ester resulting from the formal condensation of benzoic acid with the hydroxy group of metronidazole. | metronidazole benzoate |
| bitolterol | The di-4-toluate ester of (+-)-N-tert-butylnoradrenaline (colterol). A pro-drug for colterol, a beta2-adrenergic receptor agonist, bitolterol is used as its methanesulfonate salt for relief of bronchospasm in conditions such as asthma, chronic bronchitis and emphysema. | bitolterol |
| brl 15572 | A hydrochloride that is the monohydrochloride salt of 3-[4-(3-chlorophenyl)piperazin-1-yl]-1,1-diphenylpropan-2-ol. A selective h5-HT1D antagonist, displaying 60-fold selectivity over h5-HT1B, and exhibiting little or no affinity for a range of other receptor types. | 3-[4-(3-chlorophenyl)piperazin-1-yl]-1,1-diphenylpropan-2-ol hydrochloride |
| brl 42810 | 2-Amino-9H-purine in which the hydrogen at position 9 is substituted by a 4-acetoxy-3-(acetoxymethyl)but-1-yl group. A prodrug of the antiviral penciclovir, it is used for the treatment of acute herpes zoster (shingles), for the treatment or suppression of recurrent genital herpes in immunocompetent patients and for the treatment of recurrent mucocutaneous herpes simplex infections in HIV infected patients. | famciclovir |
| capecitabine | A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers. | capecitabine |
| carbimazole | A member of the class of imidazoles that is methimazole in which the nitrogen bearing a hydrogen is converted into its ethoxycarbonyl derivative. A prodrug for methimazol, carbimazole is used for the treatment of hyperthyroidism. | carbimazole |
| cefamandole nafate | A cephalosporin prodrug having (R)-O-formylmandelamido and N-methylthiotetrazole side-groups. | cefamandole nafate |
| cefditoren pivoxil | The pivaloyloxymethyl ester prodrug of cefditoren. | cefditoren pivoxil |
| cefotiam hexetil | The 1-(cyclohexyloxycarbonyloxy)ethyl ester of cefotiam. It is used as its dihydrochloride salt as a prodrug for cefotiam. | cefotiam hexetil ester |
| cefpodoxime proxetil | The 1-[(isopropoxycarbonyl)oxy]ethyl (proxetil) ester prodrug of cefpodoxime. After swallowing, hydrolysis of the ester group occurs in the intestinal epithelium, to release active cefpodoxime in the bloodstream. It is used to treat acute otitis media, pharyngitis, and sinusitis. | cefpodoxime proxetil |
| cgs 12066b | A maleate salt that is the dimaleate salt of 4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline. A 5-hydroxytryptamine receptor 1B (5-HT1B) full agonist, 10-fold selective over 5-HT1A and 1000-fold selective over 5-HT2C receptors. Centrally active following systemic administration. | 4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline dimaleate |
| chlorazepate | A 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively. | clorazepic acid |
| cilazapril, anhydrous | A pyridazinodiazepine resulting from the formal condensation of the carboxy group of cilazaprilat with ethanol. It is a drug used in the treatment of hypertension and heart failure. | cilazapril |
| clorazepate dipotassium | The compound of monopotassium clorazepate with potassium hydroxide. It is used for the management of anxiety disorders, for the short-term relief of anxiety, as adjunctive therapy in the management of epilepsy, and for the symptomatic relief of acute alcohol withdrawal. | dipotassium clorazepate |
| codeine | A morphinane alkaloid found in the opium poppy, Papaver somniferum var. album; has analgesic, anti-tussive and anti-diarrhoeal properties. | codeine |
| cyc 682 | A nucleoside analogue resulting from the formal condensation of the carboxy group of hexadecanoic acid with the amino group of CNDAC. It is the prodrug of CNDAC and is currently in clinical development for the treatment of acute myeloid leukemia (AML). | sapacitabine |
| dabigatran etexilate | An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amino group of ethyl N-pyridin-2-yl-beta-alaninate. A prodrug for dabigatran, a thrombin inhibitor and anticoagulant which is used for the prevention of stroke and systemic embolism. | dabigatran etexilate |
| dabigatran etexilate | An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amino group of ethyl N-pyridin-2-yl-beta-alaninate. A prodrug for dabigatran, a thrombin inhibitor and anticoagulant which is used for the prevention of stroke and systemic embolism. | dabigatran etexilate |
| dacarbazine | A monocarboxylic acid amide that is 1H-imidazole-4-carboxamide which is substituted at position 5 by a 3,3-dimethyltriaz-1-en-1-yl group. It is used for the treatment of metastatic malignant melanoma, and in combination with other drugs for the treatment of Hodgkin's disease and soft-tissue sarcoma. | dacarbazine |
| dextromethorphan | A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough. | dextromethorphan |
| diloxanide furoate | A carboxylic ester resulting from the formal condensation of the carboxy group of furan-2-carboxylic acid with the hydroxy group of 2,2-dichloro-N-(4-hydroxyphenyl)-N-methylacetamide. It is a drug used for the treatment of asymptomatic amebiasis. | diloxanide furoate |
| dipivefrin | The dipivalate ester of (+-)-epinephrine (racepinephrine). A pro-drug of epinephrine, the hydrochloride is used topically as eye drops to reduce intra-ocular pressure in the treatment of open-angle glaucoma or ocular hypertension. | dipivefrin |
| dipyrone | A pyrazole that is antiipyrine substituted at C-4 by a methyl(sulfomethyl)amino group, the sodium salt of which, metamizole sodium, was widely used as a powerful analgesic and antipyretic, but withdrawn from many markets from the 1970s due to a risk of causing risk of causing agranulocytosis. | metamizole |
| dipyrone | An organic sodium salt of antipyrine substituted at C-4 by a methyl(sulfonatomethyl)amino group, commonly used as a powerful analgesic and antipyretic. | metamizole sodium |
| dirithromycin | The hemi-aminal resulting from the condensation of the erythromycin derivative (9S)-erythromycyclamine with 2-(2-methoxyethoxy)acetaldehyde. As the oxazine ring containing the hemi-aminal group is unstable under both acidic and alkaline conditions, dirithromycin functions as a more lipid-soluble prodrug for (9S)-erythromycyclamine. Administered as enteric coated tablets to protect it from acid catalysed hydrolysis in the stomach, it is used to treat respiratory tract, skin, and soft tissue infections caused by susceptible organisms. | dirithromycin |
| doxifluridine | A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase. | doxifluridine |
| droxicam | An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respectively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis. | droxicam |
| droxidopa | A serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension | droxidopa |
| enalapril | A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration). | enalapril |
| enalapril maleate | The maleic acid salt of enalapril. It contains one molecule of maleic acid for each molecule of enalapril. Following oral administration, the ethyl ester group of enalapril is hydrolysed to afford the corresponding carboxylic acid, enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is thus a prodrug for enalaprilat (which, unlike enalapril, is not absorbed by mouth), and its maleate is used in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. | enalapril maleate |
| etanidazole | A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells. | etanidazole |
| etc-1002 | An alpha,omega-dicarboxylic acid that is pentadecanedioic acid which is substituted by methyl groups groups at positions 2 and 14, and by a hydroxy group at position 8. It is a drug used for the treatment of high LDL cholesterol, which is sometimes referred to as 'bad cholesterol'. | bempedoic acid |
| ethionamide | A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide. | ethionamide |
| fingolimod | An aminodiol that consists of propane-1,3-diol having amino and 2-(4-octylphenyl)ethyl substituents at the 2-position. It is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis. A prodrug, fingolimod is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate, a structural analogue of sphingosine 1-phosphate. | fingolimod |
| fingolimod hydrochloride | The hydrochloride salt of 2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol (fingolimod). | fingolimod hydrochloride |
| flucytosine | An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections. | flucytosine |
| fludarabine phosphate | A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas. | fludarabine phosphate |
| fluphenazine depot | The prodrug of fluphenazine, an antipsychotic drug used for the symptomatic management of psychosis in patients with schizophrenia. | fluphenazine decanoate |
| fluticasone furoate | A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a 2-furoyl substituent at position 17. Used in combination with vilanterol trifenate for treatment of bronchospasm associated with chronic obstructive pulmonary disease. | fluticasone furoate |
| fosamprenavir | A sulfonamide with a structure based on that of sulfanilamide substituted on the sulfonamide nitrogen by a (2R,3S)-4-phenyl-2-(phosphonooxy)-3-({[(3S)-tetrahydrofuran-3-yloxy]carbonyl}amino)butyl group. It is a pro-drug of the HIV protease inhibitor and antiretroviral drug amprenavir. | fosamprenavir |
| fosaprepitant | A morpholine derivative that is the (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl ether of (3-{[(2R,3S)-3-(4-fluorophenyl)-2-hydroxymorpholin-4-yl]methyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid. | fosaprepitant |
| fosfluconazole | | Fosfluconazole |
| gemcitabine | A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. | gemcitabine |
| gs-7340 | An L-alanine derivative that is isopropyl L-alaninate in which one of the amino hydrogens is replaced by an (S)-({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)(phenoxy)phosphoryl group. A prodrug for tenofovir, it is used (as the fumarate salt) in combination therapy for the treatment of HIV-1 infection. | tenofovir alafenamide |
| heroin | A morphinane alkaloid that is morphine bearing two acetyl substituents on the O-3 and O-6 positions. As with other opioids, heroin is used as both an analgesic and a recreational drug. Frequent and regular administration is associated with tolerance and physical dependence, which may develop into addiction. Its use includes treatment for acute pain, such as in severe physical trauma, myocardial infarction, post-surgical pain, and chronic pain, including end-stage cancer and other terminal illnesses. | heroin |
| imidapril | A member of the class of imidazolidines that is (4S)-1-methyl-2-oxoimidazolidine-4-carboxylic acid in which the hydrogen of the imidazolidine nitrogen has been substituted by (1S)-1-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}ethyl group. It is the prodrug for imidaprilat, an ACE inhibitor used for the treatment of chronic heart failure. | imidapril |
| irinotecan | A member of the class of pyranoindolizinoquinolines that is the carbamate ester obtained by formal condensation of the carboxy group of [1,4'-bipiperidine]-1'-carboxylic acid with the phenolic hydroxy group of (4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2- hydrochloride]quinoline-3,14-dione. Used (in the form of its hydrochloride salt trihydrate) in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. It is converted via hydrolysis of the carbamate linkage to its active metabolite, SN-38, which is ~1000 times more active. | irinotecan |
| irinotecan hydrochloride | A hydrochloride obtained by combining irinotecan with one molar equivalent of hydrochloric acid. Used (in the form of its trihydrate) in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. It is converted via hydrolysis of the carbamate linkage to its active metabolite, SN-38, which is ~1000 times more active. | irinotecan hydrochloride (anhydrous) |
| jte 607 | The dihydrochloride salt of JTE-607. It is a cytokine inhibitor which suppresses the production of proinflammatory cytokines such as interleukin (IL-1beta), IL-6, IL-8, granulocyte macrophage colony stimulating factor (GM-CSF), and tumor necrosis factor (TNF-alpha). It acts as a pro-drug which is cleaved by carboxylesterase 1 (CES1) to its active free acid form, which then binds to cleavage and polyadenylation specificity factor 3 (CPSF3). | JTE-607 dihydrochloride |
| lamivudine | A monothioacetal that consists of cytosine having a (2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl moiety attached at position 1. An inhibitor of HIV-1 reverse transcriptase, it is used as an antiviral in the treatment of AIDS and hepatitis B. | lamivudine |
| latanoprost | A prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension. | latanoprost |
| leflunomide | A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide. | leflunomide |
| lenampicillin | A penicillanic acid ester that is the (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester of ampicillin. It is a prodrug of ampicillin. | lenampicillin |
| levodopa | An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease | L-dopa zwitterion; L-dopa |
| lovastatin | A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom). | lovastatin |
| loxoprofen | A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-[(2-oxocyclopentyl)methyl]phenyl group. A prodrug that is rapidly converted into its active trans-alcohol metabolite following oral administration. | loxoprofen |
| lucanthone | A thioxanthen-9-one compound having a methyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. Formerly used for the treatment of schistosomiasis. It is a prodrug, being metabolised to hycanthone. | lucanthone |
| mestranol | A terminal acetylenic compound that is (17alpha)-17-ethynylestra-1(10),2,4-triene substituted by a methoxy group at position 3 and a hydroxy group at position 17. | mestranol |
| methyl 5-aminolevulinate | The methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumulation of protoporphyrin IX in the skin lesions to which the cream has been applied. Subsequent illumination with red light results in the generation of toxic singlet oxygen that destroys cell membranes and thereby kills the tumour cells. | methyl 5-aminolevulinate |
| methyl 5-aminolevulinate hydrochloride | The hydrochloride salt of methyl 5-aminolevulinate. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application results in an accumulation of protoporphyrin IX in the skin lesions to which the cream has been applied. Subsequent illumination with red light results in the generation of toxic singlet oxygen that destroys cell membranes and thereby kills the tumour cells. | methyl 5-aminolevulinate hydrochloride |
| methylprednisolone suleptanate | An organic sodium salt that is the monosodium salt of methylprednisolone 21-suleptanic acid ester. It is a prodrug of methylprednisolone developed by Pharmacia Corp for the treatment of asthma. | methylprednisolone suleptanate |
| metronidazole | A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death. | metronidazole |
| midodrine | An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine. | midodrine |
| ML-210 | An N-acylpiperazine that is piperazine substituted by 5-methyl-4-nitro-1,2-oxazole-3-carbonyl and bis(4-chlorophenyl)methyl groups at positions 1 and 4, respectively. It is a glutathione peroxidase 4 (GPX4) inhibitor which induces ferroptosis in cancer cells expressing the RAS oncogene. | ML-210 |
| molnupiravir | A nucleoside analogue that is N(4)-hydroxycytidine in which the 5'-hydroxy group is replaced by a (2-methylpropanoyl)oxy group. It is the prodrug of the active antiviral ribonucleoside analog N(4)-hydroxycytidine (EIDD-1931), has activity against a number of RNA viruses including SARS-CoV-2, MERS-CoV, and seasonal and pandemic influenza viruses. It is currently in phase III trials for the treatment of patients with COVID-19. | molnupiravir |
| mycophenolate mofetil | A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases. | mycophenolate mofetil |
| N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide | A hydrobromide salt prepared from N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol and one equivalent of hydrogen bromide. Dopamine D1-like receptor partial agonist (Ki values are 1.18, 7.56, 920 and 399 nM for rat D1, D5, D2 and D3 receptors respectively). May act as an antagonist in vivo, producing anti-Parkinsonian effects and antagonising the behavioral effects of cocaine. | N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide |
| nabumetone | A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs. | nabumetone |
| naproxen-n-butyl nitrate | A carboxylic ester obtained by formal condensation of the carboxy group of naproxen with the hydroxy group of 4-(nitrooxy)butanol. A cyclooxygenase-inhibiting nitric oxide donator that is metabolised to naproxen and a nitric oxide donating moiety, effective in treatment of osteoarthritis. | naproxcinod |
| nelarabine | A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G). | nelarabine |
| nepafenac | A monocarboxylic acid amide that is amfenac in which the carboxylic acid group has been converted into the corresponding carboxamide. It is a prodrug for amfenac, used in eye drops to treat pain and inflammation following cataract surgery. | nepafenac |
| nitroglycerin | A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain. | nitroglycerin |
| olsalazine | An azobenzene that consists of two molecules of 4-aminosalicylic acid joined by an azo linkage. A prodrug for mesalazine, an anti-inflammatory drug, it is used (as the disodium salt) in the treatment of inflammatory bowel disease. | olsalazine |
| oseltamivir | A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza. | oseltamivir |
| parecoxib | An N-acylsulfonamide resulting from the formal condensation of valdecoxib with propionic acid. It is a prodrug for valdecoxib. | parecoxib |
| penamecillin | A penicillanic acid ester that is the acetoxymethyl ester of benzylpenicillin. It is a prodrug for benzylpenicillin. | penamecillin |
| PF-07304814 | An indolecarboxamide resulting from the formal condensation of the carboxy group of 4-methoxy-1H-indole-2-carboxylic acid with the primary amino group of N-[(2S)-3-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]-4-(phosphonooxy)butan-2-yl]-L-leucinamide. It is the phosphate prodrug of PF-00835231, an anticoronaviral agent. | PF-07304814 |
| pivampicillin | A penicillanic acid ester that is the pivaloyloxymethyl ester of ampicillin. It is a prodrug of ampicillin. | pivampicillin |
| pn 401 | An acetate ester that is uracil in which the three hydroxy hydrogens are replaced by acetate group. A prodrug for uridine, it is used for the treatment of hereditary orotic aciduria and for management of fluorouracil toxicity. | uridine triacetate |
| ppi-0903 | A cephalosporin having [4-(1-methylpyridinium-4-yl)-1,3-thiazol-2-yl]sulfanyl and {(2Z)-2-(ethoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl}amino side groups located at positions 3 and 7 respectively. The N-phospho prodrug of ceftaroline, a broad-spectrum antibiotic active against methicillin-resistant Staphylococcus aureus (MRSA). It is used for the treatment of adults with acute bacterial skin and skin structure infections. | ceftaroline fosamil |
| prednisolone phosphate | A synthetic glucocorticoid resulting from the formal condensation of the 21-hydroxy group of prednisolone with one of the hydroxy groups of phosphoric acid. It is a prodrug for prednisolone that is activated in vivo by phosphatases. | prednisolone phosphate |
| prednisone | A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid. | prednisone |
| proglumetacin | A carboxylic ester obtained by formal condensation of the carboxy group of indometacin with the hydroxy group of 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl N(2)-benzoyl-N,N-dipropyl-alpha-glutaminate. Used (as its dimaleate salt) to control pain and inflammation associated with musculoskeletal and joint disorders. Following oral administration, it is metabolised to indometacin and proglumide, a drug with antisecretory effects that helps prevent injury to the stomach lining. | proglumetacin |
| psilocybin | A tryptamine alkaloid that is N,N-dimethyltryptamine carrying an additional phosphoryloxy substituent at position 4. The major hallucinogenic alkaloid isolated from Psilocybe mushrooms (also known as Teonanacatl or "magic mushrooms"). | psilocybin |
| pyrazinamide | A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis. | pyrazinecarboxamide |
| quinapril | A member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure. | quinapril |
| ramipril | A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure. | ramipril |
| rubitecan | A pyranoindolizinoquinoline that is camptothecin in which the hydrogen at position 9 has been replaced by a nitro group. It is a prodrug for 9-aminocamptothecin. | rubitecan |
| rx-3117 | A triol that is (1S,2R)-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol which is substituted by a 4-amino-2-oxopyrimidin-1(2H)-yl group at position 5. It is a cytidine analog which exhibits anticancer activity in several cancers, including gemcitabine-resistant tumours. | roducitabine |
| s 8932 | A carboxylic ester resulting from the formal condensation of the carboxy group of N-[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]-L-alanine with the hydroxy group of 2-ethylbutan-1-ol. A broad-spectrum antiviral prodrug with potent in vitro antiviral activity against a diverse panel of RNA viruses such as Ebola virus, MERS-CoV and SARS-CoV. It is currently in Phase III clinical trials for the treatment of Covid-19 in adults. | remdesivir |
| salicin | An aryl beta-D-glucoside that is salicyl alcohol in which the phenolic hydrogen has been replaced by a beta-D-glucosyl residue. | salicin |
| salicylsalicylic acid | A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes. | salsalate |
| selexipag | A member of the class of pyrazines that is N-(methanesulfonyl)-2-{4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetamide carrying two additional phenyl substituents at positions 5 and 6 on the pyrazine ring. An orphan drug used for the treatment of pulmonary arterial hypertension. It is a prodrug for ACT-333679 (the free carboxylic acid). | selexipag |
| simvastatin | A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug. | simvastatin |
| sk&f 77434 | A hydrobromide salt prepared from N-allyl-1-phenyl-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol and one equivalent of hydrogen bromide. Selective dopamine D1-like receptor partial agonist (IC50 values are 19.7 and 2425 nM for binding to D1-like and D2-like receptors respectively). Centrally active following systemic administration in vivo. | N-allyl-1-phenyl-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide |
| sofosbuvir | A nucleotide conjugate that is used in combination with ledipasvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection. | sofosbuvir |
| spirapril | | spirapril |
| sulindac | A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions. | sulindac |
| suxibuzone | A pyrazolidine that is phenylbutazone which is substituted by a 3-carboxypropanoylmethyl group at the 4-position. Suxibuzone is a prodrug for phenylbutazone and is commonly used as an anti-inflammatory drug in horses. | suxibuzone |
| tak 491 | A carboxylic ester obtained by formal condensation of the carboxy group of azilsartan with the hydroxy group of 4-(hydroxymethyl)-5-methyl-1,3-dioxol-2-one. A prodrug for azilsartan, it is used for treatment of hypertension. | azilsartan medoxomil |
| talampicillin | A penicillanic acid ester that is the 1-phthalidyl ester of ampicillin. It is a prodrug of ampicillin. | talampicillin |
| tazarotene | The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin. | tazarotene |
| tedizolid phosphate | A phosphate monoester resulting from the formal condensation of equimolar amounts of phosphoric acid with the hydroxy group of tedizolid . It is a prodrug of tedizolid, used for the treatment of acute bacterial skin infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis. | tedizolid phosphate |
| temozolomide | An imidazotetrazine that is 3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine which is substituted at positions 3, 4, and 8 by methyl, oxo, and carboxamide groups, respectively. A prodrug for MTIC (5-(3-methyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide, formed by spontaneous hydrolysis of temozolomide in the body), it is used as an oral alkylating agent for the treatment of newly diagnosed malignant glioblastoma multiforme (concomitantly with radiotherapy) and malignant melanoma. | temozolomide |
| tenofovir disoproxil fumarate | A fumarate salt prepared from equimolar amounts of tenofovir disoproxil and fumaric acid. It is used in combination therapy for the treatment of HIV infection. | tenofovir disoproxil fumarate |
| tiazofurin | A C-glycosyl compound that is 1,3-thiazole-4-carboxamide in which the hydrogen at position 2 has been replaced by a beta-D-ribofuranosyl group. It is metabolised to thiazole-4-carboxamide adenine dinucleotide (TAD), a selective inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase). | tiazofurine |
| trandolapril | A heterobicylic compound that is (2S,3aR,7aS)-1-[(2S)-2-aminopropanoyl]octahydro-1H-indole-2-carboxylic acid in which the hydrogen of the amino group is substituted by a (2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl group. It is a angiotensin-converting enzyme inhibitor and a prodrug used for the treatment of hypertension. | trandolapril |
| travoprost | The isopropyl ester of prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophthalmic solutions of travoprost are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. It is a pro-drug; the isopropyl ester group is hydrolysed by esterases in the cornea to the biologically active free acid, fluprostenol. | travoprost |
| tributyrin | A triglyceride obtained by formal acylation of the three hydroxy groups of glycerol by butyric acid. | tributyrin |
| uf 021 | The isopropyl ester of unoprostone. | isopropyl unoprostone |
| uracil | A common and naturally occurring pyrimidine nucleobase in which the pyrimidine ring is substituted with two oxo groups at positions 2 and 4. Found in RNA, it base pairs with adenine and replaces thymine during DNA transcription. | uracil |
| valganciclovir | The L-valinyl ester of ganciclovir, into which it is rapidly converted by intestinal and hepatic esterases. It is a synthetic analogue of 2'-deoxyguanosine. | valganciclovir |
| varespladib methyl | A methyl ester resulting from the formal condensation of the carboxy group of varespladib with methanol. It is a potential therapy for the treatment of snakebite envenomings in which toxicity depends on the action of PLA2s. | varespladib methyl |
| ximelagatran | A member of the class of azetidines that is melagatran in which the carboxylic acid group has been converted to the corresponding ethyl ester and in which the amidine group has been converted into the corresponding amidoxime. A prodrug for melagatran, ximelagatran was the first orally available direct thrombin inhibitor to be brought to market as an anticoagulant, but was withdrawn in 2006 following reports of it causing liver damage. | ximelagatran (hydroxylamine form); ximelagatran |
| zofenopril | A proline derivative that is 4-(phenylsulfanyl)-L-proline in which the amine proton is replaced by a (2S)-3-(benzoylsulfanyl)-2-methylpropanoyl group. A prodrug for zofenoprilat. | zofenopril |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 22.7846 | 1 | 3 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 27.2854 | 1 | 4 |
| 67.9K protein | Vaccinia virus | Potency | 19.9950 | 2 | 5 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 31.9855 | 4 | 21 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 27.9315 | 2 | 9 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 21.2958 | 1 | 9 |
| alpha-galactosidase | Homo sapiens (human) | Potency | 39.0743 | 2 | 3 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 13.1570 | 1 | 3 |
| AR protein | Homo sapiens (human) | Potency | 14.4755 | 12 | 164 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 16.3346 | 2 | 20 |
| arylsulfatase A | Homo sapiens (human) | Potency | 15.0595 | 1 | 8 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 12.1763 | 4 | 8 |
| Ataxin-2 | Homo sapiens (human) | Potency | 7.9476 | 2 | 10 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 10.7964 | 5 | 8 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 7.1297 | 2 | 14 |
| atrial natriuretic peptide receptor 1 precursor | Homo sapiens (human) | Potency | 23.9341 | 1 | 1 |
| beta-2 adrenergic receptor | Homo sapiens (human) | Potency | 25.9207 | 1 | 2 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 44.9789 | 3 | 13 |
| BRCA1 | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 65.3802 | 1 | 6 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 26.6297 | 1 | 6 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 33.4915 | 1 | 1 |
| caspase-3 | Homo sapiens (human) | Potency | 26.6297 | 1 | 6 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 33.4915 | 1 | 1 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 21.3866 | 3 | 41 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 9.3792 | 2 | 7 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 23.0837 | 1 | 17 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 19.6744 | 2 | 17 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 24.3493 | 1 | 5 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 25.0094 | 1 | 4 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 18.3658 | 2 | 6 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 31.9094 | 1 | 4 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 6.3187 | 1 | 11 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 12.8538 | 2 | 4 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 21.9243 | 1 | 6 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 18.3658 | 2 | 6 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 71.9751 | 2 | 16 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 13.9100 | 1 | 6 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 22.1060 | 1 | 2 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 15.8416 | 1 | 20 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 19.0476 | 1 | 16 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 2.5119 | 1 | 1 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 11.5948 | 2 | 18 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 13.3936 | 2 | 30 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 9.6133 | 1 | 22 |
| D(3) dopamine receptor isoform e | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 5.3138 | 1 | 2 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 32.6672 | 1 | 2 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 19.5957 | 2 | 2 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 58.8530 | 2 | 9 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 12.6397 | 1 | 5 |
| dopamine D1 receptor | Homo sapiens (human) | Potency | 4.1044 | 1 | 2 |
| endonuclease IV | Escherichia coli | Potency | 20.3620 | 2 | 4 |
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | Potency | 9.1726 | 1 | 2 |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | Potency | 9.1726 | 1 | 2 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 13.6879 | 10 | 168 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 16.7617 | 3 | 23 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 17.6028 | 10 | 131 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 18.1382 | 1 | 21 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 12.7445 | 4 | 50 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 24.2020 | 3 | 20 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 30.8137 | 3 | 6 |
| fructose-bisphosphate aldolase A | Oryctolagus cuniculus (rabbit) | Potency | 63.0957 | 1 | 1 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 20.7327 | 1 | 10 |
| G | Vesicular stomatitis virus | Potency | 15.8416 | 1 | 20 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 11.5948 | 1 | 9 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 11.5948 | 1 | 9 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 11.5948 | 1 | 9 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 11.5948 | 1 | 9 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 11.5948 | 1 | 9 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 11.5948 | 1 | 9 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 11.5948 | 1 | 9 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 11.5948 | 1 | 9 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 11.5948 | 1 | 9 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 11.5948 | 1 | 9 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 11.5948 | 1 | 9 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 11.5948 | 1 | 9 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 11.5948 | 1 | 9 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 11.5948 | 1 | 9 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 11.5948 | 1 | 9 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 11.5948 | 1 | 9 |
| geminin | Homo sapiens (human) | Potency | 7.4931 | 4 | 49 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 18.4408 | 3 | 47 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 16.0254 | 1 | 6 |
| GLS protein | Homo sapiens (human) | Potency | 21.0391 | 2 | 8 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 11.8419 | 1 | 3 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 17.1820 | 5 | 45 |
| glucokinase regulatory protein | Homo sapiens (human) | Potency | 5.0119 | 1 | 1 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 15.6139 | 1 | 13 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 8.5900 | 1 | 2 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 11.4642 | 1 | 2 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 39.9816 | 2 | 14 |
| hemoglobin subunit beta | Homo sapiens (human) | Potency | 1.9377 | 5 | 8 |
| hexokinase-4 isoform 1 | Homo sapiens (human) | Potency | 5.0119 | 1 | 1 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 20.8053 | 2 | 10 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 28.4466 | 1 | 8 |
| histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 7.5110 | 2 | 7 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 35.3863 | 2 | 16 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 35.4815 | 1 | 5 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 15.8416 | 1 | 20 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 10.4353 | 3 | 4 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 12.0869 | 3 | 4 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 45.2177 | 2 | 9 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 13.2258 | 3 | 14 |
| IDH1 | Homo sapiens (human) | Potency | 14.9342 | 1 | 9 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 24.4714 | 2 | 3 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 15.8416 | 1 | 40 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 11.2202 | 1 | 1 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 12.9244 | 1 | 2 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 12.9244 | 1 | 2 |
| Interferon beta | Homo sapiens (human) | Potency | 18.6599 | 3 | 40 |
| interleukin 8 | Homo sapiens (human) | Potency | 66.8242 | 1 | 1 |
| isocitrate dehydrogenase 1, partial | Homo sapiens (human) | Potency | 42.8000 | 1 | 2 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 6.7904 | 2 | 29 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 21.8797 | 3 | 13 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 18.8007 | 2 | 3 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 26.2870 | 1 | 6 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 23.1845 | 2 | 14 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 14.3523 | 2 | 6 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 9.4110 | 2 | 7 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 30.4653 | 1 | 7 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 10.5924 | 1 | 3 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 14.7059 | 1 | 4 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 1.7388 | 1 | 3 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 25.7719 | 3 | 54 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 11.9530 | 1 | 10 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 29.8139 | 2 | 10 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 12.7487 | 1 | 4 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 14.7854 | 2 | 11 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 10.5768 | 1 | 8 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 18.3849 | 3 | 51 |
| P53 | Homo sapiens (human) | Potency | 56.2341 | 1 | 2 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 119.0470 | 1 | 2 |
| Parkin | Homo sapiens (human) | Potency | 16.1125 | 2 | 3 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 68.8303 | 2 | 3 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 8.3783 | 2 | 23 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 55.8062 | 1 | 7 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 25.9819 | 4 | 24 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 19.6287 | 5 | 22 |
| phosphoglycerate kinase | Trypanosoma brucei brucei TREU927 | Potency | 12.1739 | 3 | 3 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 62.1753 | 3 | 16 |
| PINK1 | Homo sapiens (human) | Potency | 23.3507 | 1 | 2 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 4.9206 | 1 | 10 |
| polyprotein | Zika virus | Potency | 20.7327 | 1 | 10 |
| polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 18.8541 | 1 | 2 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 12.0849 | 1 | 5 |
| PPM1D protein | Homo sapiens (human) | Potency | 20.6453 | 1 | 10 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 23.8803 | 3 | 25 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 47.3936 | 1 | 2 |
| progesterone receptor | Homo sapiens (human) | Potency | 21.7866 | 3 | 18 |
| pyruvate kinase | Leishmania mexicana mexicana | Potency | 13.7312 | 5 | 7 |
| pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 24.0283 | 2 | 5 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 125.8920 | 1 | 1 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 24.9618 | 1 | 3 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 12.6689 | 2 | 51 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 2.8178 | 1 | 4 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 26.1605 | 1 | 3 |
| relaxin receptor 1 isoform 1 | Homo sapiens (human) | Potency | 17.7828 | 1 | 1 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 22.5552 | 3 | 48 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 15.1848 | 3 | 31 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 1.5586 | 2 | 2 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 27.7492 | 1 | 4 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 28.0900 | 3 | 17 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 28.0900 | 3 | 17 |
| Smad3 | Homo sapiens (human) | Potency | 10.5722 | 1 | 8 |
| snurportin-1 | Homo sapiens (human) | Potency | 24.4714 | 2 | 3 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 14.5874 | 2 | 28 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 10.1845 | 2 | 16 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 24.0602 | 1 | 6 |
| TDP1 protein | Homo sapiens (human) | Potency | 13.1942 | 2 | 72 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 25.0598 | 1 | 6 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 22.3211 | 4 | 19 |
| Thrombopoietin | Homo sapiens (human) | Potency | 7.9433 | 2 | 2 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 25.0521 | 3 | 55 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 90.2675 | 2 | 5 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 18.1725 | 6 | 22 |
| thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 41.3778 | 2 | 2 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 44.6684 | 1 | 1 |
| tumor susceptibility gene 101 protein | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 20.7491 | 1 | 1 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 4.9206 | 1 | 10 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 4.9206 | 1 | 10 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 37.0706 | 2 | 14 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 28.7300 | 2 | 20 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 17.8408 | 4 | 18 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 65.0749 | 1 | 6 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 15.6139 | 1 | 13 |
| WRN | Homo sapiens (human) | Potency | 5.4979 | 2 | 2 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | IC50 | 2.5768 | 16 | 18 |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Schizosaccharomyces pombe 972h- | IC50 | 95.2000 | 1 | 1 |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | Ki | 34.0013 | 2 | 2 |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | IC50 | 0.0459 | 11 | 12 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| Acetylcholinesterase | Electrophorus electricus (electric eel) | IC50 | 100.0000 | 1 | 1 |
| Acetylcholinesterase | Homo sapiens (human) | IC50 | 20.3654 | 5 | 5 |
| Acetylcholinesterase | Rattus norvegicus (Norway rat) | IC50 | 30.0000 | 1 | 1 |
| Acetylcholinesterase | Homo sapiens (human) | Ki | 0.0505 | 1 | 1 |
| Acetylcholinesterase | Tetronarce californica (Pacific electric ray) | Ki | 0.0264 | 1 | 1 |
| Acyl-CoA desaturase 1 | Mus musculus (house mouse) | IC50 | 0.0080 | 1 | 1 |
| Acyl-CoA:cholesterol acyltransferase | Oryctolagus cuniculus (rabbit) | IC50 | 16.8000 | 1 | 1 |
| Adenosine receptor A1 | Homo sapiens (human) | IC50 | 26.7200 | 1 | 1 |
| Adenosine receptor A1 | Homo sapiens (human) | Ki | 15.5860 | 1 | 1 |
| Adenylate cyclase type 10 | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| Albumin | Homo sapiens (human) | Ki | 26,302,700,000.0000 | 1 | 1 |
| Alcohol dehydrogenase E chain | Equus caballus (horse) | Ki | 10,000.0000 | 1 | 1 |
| Alcohol dehydrogenase S chain | Equus caballus (horse) | Ki | 10,000.0000 | 1 | 1 |
| Aldo-keto reductase family 1 member B1 | Bos taurus (cattle) | IC50 | 0.2930 | 1 | 1 |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | IC50 | 2.6900 | 1 | 1 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | IC50 | 4.1583 | 1 | 4 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | Ki | 4.1237 | 1 | 4 |
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | IC50 | 2.6900 | 1 | 1 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | IC50 | 3.1710 | 1 | 1 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | Ki | 0.4610 | 1 | 1 |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | IC50 | 10.8470 | 1 | 2 |
| Amyloid-beta precursor protein | Homo sapiens (human) | IC50 | 4.7000 | 2 | 2 |
| Androgen receptor | Rattus norvegicus (Norway rat) | IC50 | 12.8093 | 3 | 4 |
| Androgen receptor | Rattus norvegicus (Norway rat) | Ki | 13.6155 | 1 | 2 |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | IC50 | 1.0061 | 4 | 9 |
| Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | IC50 | 0.0696 | 3 | 3 |
| Angiotensin-converting enzyme | Homo sapiens (human) | IC50 | 0.6569 | 9 | 20 |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | IC50 | 0.0742 | 1 | 2 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 | 128.2769 | 1 | 26 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | IC50 | 154.3636 | 6 | 11 |
| Aurora kinase A | Homo sapiens (human) | IC50 | 0.3268 | 3 | 5 |
| Aurora kinase A | Homo sapiens (human) | Ki | 1.3680 | 1 | 1 |
| Aurora kinase B | Homo sapiens (human) | IC50 | 1.7751 | 5 | 7 |
| Aurora kinase B | Homo sapiens (human) | Ki | 0.0004 | 1 | 1 |
| Aurora kinase C | Homo sapiens (human) | IC50 | 0.0627 | 2 | 4 |
| bcl-2-related protein A1 | Mus musculus (house mouse) | IC50 | 100.0000 | 2 | 2 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 222.9898 | 6 | 44 |
| Bile salt export pump | Rattus norvegicus (Norway rat) | IC50 | 399.7000 | 1 | 3 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 125.4792 | 2 | 24 |
| Canalicular multispecific organic anion transporter 1 | Rattus norvegicus (Norway rat) | Ki | 7.9500 | 1 | 1 |
| Cannabinoid receptor 1 | Homo sapiens (human) | IC50 | 28.5400 | 1 | 1 |
| Cannabinoid receptor 1 | Homo sapiens (human) | Ki | 22.5320 | 1 | 1 |
| Capsid protein | Hepatitis B virus | IC50 | 50.0500 | 2 | 2 |
| Carbonic anhydrase 1 | Homo sapiens (human) | IC50 | 375.5000 | 1 | 2 |
| Carbonic anhydrase 1 | Homo sapiens (human) | Ki | 30.0000 | 2 | 2 |
| Carbonic anhydrase 12 | Homo sapiens (human) | Ki | 50.0000 | 1 | 1 |
| Carbonic anhydrase 2 | Homo sapiens (human) | IC50 | 375.5000 | 1 | 2 |
| Carbonic anhydrase 2 | Homo sapiens (human) | Ki | 30.0000 | 2 | 2 |
| Carbonic anhydrase 5A, mitochondrial | Homo sapiens (human) | Ki | 0.1309 | 1 | 1 |
| Carbonic anhydrase 9 | Homo sapiens (human) | Ki | 50.0000 | 1 | 1 |
| Carboxylic ester hydrolase | Rattus norvegicus (Norway rat) | IC50 | 0.0030 | 1 | 1 |
| Cereblon isoform 4 | Magnetospirillum gryphiswaldense | Ki | 24.5000 | 2 | 2 |
| Chain A, Acetylcholinesterase | Tetronarce californica (Pacific electric ray) | Ki | 0.0264 | 1 | 1 |
| Chain A, Antigen Cd11a (p180) | Homo sapiens (human) | IC50 | 2.4000 | 1 | 1 |
| Chain A, DEOXYNUCLEOSIDE KINASE | Drosophila melanogaster (fruit fly) | IC50 | 0.7600 | 1 | 1 |
| Chain A, Histamine N-methyltransferase | Homo sapiens (human) | Ki | 0.0186 | 1 | 4 |
| Chain A, Uracil-DNA Glycosylase | Thermus thermophilus | Ki | 0.0880 | 1 | 1 |
| Cholinesterase | Equus caballus (horse) | IC50 | 0.1193 | 1 | 1 |
| Cholinesterase | Homo sapiens (human) | IC50 | 0.0033 | 4 | 4 |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | IC50 | 14.3600 | 1 | 1 |
| Cystathionine gamma-lyase | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| Cytochrome P450 1A2 | Homo sapiens (human) | IC50 | 35.1667 | 2 | 3 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 | 36.9967 | 2 | 3 |
| Cytochrome P450 2D1 | Rattus norvegicus (Norway rat) | IC50 | 792.0000 | 1 | 2 |
| Cytochrome P450 2D26 | Rattus norvegicus (Norway rat) | IC50 | 121.8000 | 1 | 2 |
| Cytochrome P450 2D3 | Rattus norvegicus (Norway rat) | IC50 | 2,053.8000 | 1 | 2 |
| Cytochrome P450 2D4 | Rattus norvegicus (Norway rat) | IC50 | 1,176.0000 | 1 | 2 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 | 50.5426 | 7 | 9 |
| Cytochrome P450 2J2 | Homo sapiens (human) | IC50 | 25.4950 | 1 | 2 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 8.4000 | 1 | 1 |
| Cytochrome P450 3A4 | Homo sapiens (human) | Ki | 24.0000 | 1 | 1 |
| D(1A) dopamine receptor | Homo sapiens (human) | Ki | 0.0012 | 1 | 1 |
| D(3) dopamine receptor | Homo sapiens (human) | IC50 | 1.9290 | 1 | 1 |
| D(3) dopamine receptor | Homo sapiens (human) | Ki | 0.6550 | 1 | 1 |
| Delta-type opioid receptor | Homo sapiens (human) | IC50 | 9.3000 | 1 | 1 |
| Delta-type opioid receptor | Mus musculus (house mouse) | IC50 | 10.0000 | 1 | 3 |
| Delta-type opioid receptor | Homo sapiens (human) | Ki | 52.2070 | 1 | 1 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Homo sapiens (human) | IC50 | 7.9333 | 3 | 3 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Mus musculus (house mouse) | IC50 | 0.0300 | 1 | 1 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Rattus norvegicus (Norway rat) | IC50 | 0.0090 | 1 | 1 |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | IC50 | 225.0000 | 1 | 1 |
| Disabled homolog 2-interacting protein | Homo sapiens (human) | Ki | 1.2600 | 1 | 1 |
| DNA-(apurinic or apyrimidinic site) endonuclease | Homo sapiens (human) | IC50 | 5.0000 | 2 | 2 |
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 | 304.2933 | 3 | 3 |
| Equilibrative nucleoside transporter 1 | Homo sapiens (human) | IC50 | 0.1900 | 1 | 1 |
| Estrogen receptor | Homo sapiens (human) | IC50 | 2.5090 | 2 | 2 |
| Estrogen receptor | Homo sapiens (human) | Ki | 0.0052 | 1 | 1 |
| Estrogen receptor 1 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Estrogen receptor beta | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | IC50 | 14.3600 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit delta | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit epsilon | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit pi | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit rho-1 | Homo sapiens (human) | IC50 | 12.9000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit theta | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Glucocorticoid receptor | Homo sapiens (human) | IC50 | 0.3823 | 3 | 3 |
| Glucocorticoid receptor | Homo sapiens (human) | Ki | 0.2608 | 2 | 2 |
| glucose-6-phosphate 1-dehydrogenase isoform b | Homo sapiens (human) | IC50 | 72.5000 | 1 | 1 |
| glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | IC50 | 27.9667 | 3 | 3 |
| Glutamate dehydrogenase 1, mitochondrial | Bos taurus (cattle) | Ki | 10,000.0000 | 1 | 1 |
| Glutamate receptor 1 | Homo sapiens (human) | Ki | 790.0000 | 1 | 1 |
| Glutamate receptor 2 | Homo sapiens (human) | Ki | 790.0000 | 1 | 1 |
| Glutamate receptor 3 | Homo sapiens (human) | Ki | 790.0000 | 1 | 1 |
| Glutamate receptor 4 | Homo sapiens (human) | Ki | 790.0000 | 1 | 1 |
| Glutamate receptor ionotropic, kainate 3 | Rattus norvegicus (Norway rat) | Ki | 790.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | Ki | 1.6800 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | Ki | 2.2460 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | Ki | 1.6800 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | Ki | 2.2460 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | Ki | 1.6800 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | Ki | 2.2460 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2C | Homo sapiens (human) | Ki | 1.6800 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | Ki | 2.2460 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2D | Homo sapiens (human) | Ki | 1.6800 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | Ki | 2.2460 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3A | Homo sapiens (human) | Ki | 1.6800 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | Ki | 2.2460 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3B | Homo sapiens (human) | Ki | 1.6800 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | Ki | 2.2460 | 1 | 1 |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | IC50 | 1.1460 | 1 | 1 |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Ki | 0.5210 | 1 | 1 |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | IC50 | 1.1460 | 1 | 1 |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Ki | 0.5210 | 1 | 1 |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | IC50 | 1.1460 | 1 | 1 |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Ki | 0.5210 | 1 | 1 |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | IC50 | 1.1460 | 1 | 1 |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | Ki | 0.5210 | 1 | 1 |
| Histone deacetylase 1 | Homo sapiens (human) | IC50 | 79.3037 | 3 | 3 |
| Histone deacetylase 1 | Homo sapiens (human) | Ki | 4.5700 | 1 | 2 |
| Histone deacetylase 11 | Homo sapiens (human) | Ki | 4.5700 | 1 | 2 |
| Histone deacetylase 2 | Homo sapiens (human) | IC50 | 45.4665 | 2 | 2 |
| Histone deacetylase 2 | Homo sapiens (human) | Ki | 4.5700 | 1 | 2 |
| Histone deacetylase 3 | Homo sapiens (human) | IC50 | 260.0000 | 1 | 1 |
| Histone deacetylase 3 | Homo sapiens (human) | Ki | 4.5700 | 1 | 2 |
| Histone deacetylase 4 | Homo sapiens (human) | IC50 | 2,000.0000 | 1 | 1 |
| Histone deacetylase 4 | Homo sapiens (human) | Ki | 4.5700 | 1 | 2 |
| Histone deacetylase 5 | Homo sapiens (human) | IC50 | 2,000.0000 | 1 | 1 |
| Histone deacetylase 5 | Homo sapiens (human) | Ki | 4.5700 | 1 | 2 |
| Histone deacetylase 6 | Homo sapiens (human) | IC50 | 128.1425 | 2 | 2 |
| Histone deacetylase 6 | Homo sapiens (human) | Ki | 4.5700 | 1 | 2 |
| Histone deacetylase 7 | Homo sapiens (human) | IC50 | 2,000.0000 | 1 | 1 |
| Histone deacetylase 7 | Homo sapiens (human) | Ki | 4.5700 | 1 | 2 |
| Histone deacetylase 8 | Homo sapiens (human) | IC50 | 93.0000 | 1 | 1 |
| Histone deacetylase 8 | Homo sapiens (human) | Ki | 4.5700 | 1 | 2 |
| Histone deacetylase 9 | Homo sapiens (human) | IC50 | 2,000.0000 | 1 | 1 |
| Histone deacetylase 9 | Homo sapiens (human) | Ki | 4.5700 | 1 | 2 |
| Insulin receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0117 | 1 | 2 |
| integrase, partial | Human immunodeficiency virus 1 | IC50 | 0.5939 | 2 | 2 |
| Integrin alpha-L | Homo sapiens (human) | IC50 | 3.0900 | 2 | 2 |
| Integrin beta-2 | Homo sapiens (human) | IC50 | 3.0900 | 2 | 2 |
| Intercellular adhesion molecule 1 | Homo sapiens (human) | IC50 | 3.7800 | 1 | 1 |
| Interstitial collagenase | Homo sapiens (human) | IC50 | 6.0600 | 1 | 1 |
| Kappa-type opioid receptor | Homo sapiens (human) | IC50 | 15.0000 | 1 | 1 |
| Kappa-type opioid receptor | Mus musculus (house mouse) | IC50 | 10.0000 | 1 | 3 |
| Kappa-type opioid receptor | Homo sapiens (human) | Ki | 25.4110 | 1 | 1 |
| Lactoperoxidase | Homo sapiens (human) | IC50 | 10.4000 | 1 | 1 |
| Lactoylglutathione lyase | Homo sapiens (human) | Ki | 69.7000 | 2 | 4 |
| Lanosterol 14-alpha demethylase | Homo sapiens (human) | IC50 | 200.0000 | 1 | 2 |
| Large neutral amino acids transporter small subunit 1 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| large T antigen | Betapolyomavirus macacae | IC50 | 100.0000 | 1 | 1 |
| lens epithelium-derived growth factor p75 | Homo sapiens (human) | IC50 | 0.5939 | 2 | 2 |
| Lysine-specific histone demethylase 1A | Homo sapiens (human) | IC50 | 3.1900 | 3 | 3 |
| Metabotropic glutamate receptor 3 | Rattus norvegicus (Norway rat) | Ki | 10,000.0000 | 1 | 2 |
| Mineralocorticoid receptor | Homo sapiens (human) | IC50 | 0.1660 | 1 | 1 |
| Mu-type opioid receptor | Homo sapiens (human) | IC50 | 0.1050 | 1 | 1 |
| Mu-type opioid receptor | Mus musculus (house mouse) | IC50 | 10.0000 | 1 | 3 |
| Mu-type opioid receptor | Homo sapiens (human) | Ki | 3.5135 | 2 | 2 |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | IC50 | 128.5750 | 3 | 4 |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | IC50 | 43.2500 | 2 | 2 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 | 123.8885 | 1 | 26 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | IC50 | 1.5560 | 1 | 1 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | Ki | 0.2170 | 1 | 1 |
| NAD-dependent protein deacetylase sirtuin-6 | Homo sapiens (human) | IC50 | 416.9000 | 1 | 1 |
| NAD-dependent protein deacylase sirtuin-5, mitochondrial | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Neuraminidase | Influenza A virus (A/Aichi/2/1968(H3N2)) | IC50 | 0.0016 | 1 | 1 |
| Neuraminidase | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | IC50 | 1.1344 | 6 | 6 |
| Neuraminidase | Influenza A virus (A/Singapore/1/1957(H2N2)) | IC50 | 0.0030 | 1 | 2 |
| Neuraminidase | Influenza A virus (A/USSR/90/1977(H1N1)) | IC50 | 27.1760 | 4 | 4 |
| Neuraminidase | Influenza B virus (B/Lee/1940) | IC50 | 0.0050 | 1 | 1 |
| Neuraminidase | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | Ki | 12.1000 | 1 | 1 |
| Neuraminidase | Influenza B virus (B/Lee/1940) | Ki | 0.0011 | 1 | 1 |
| Neuraminidase | Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) | IC50 | 0.0043 | 2 | 2 |
| Neuraminidase | Influenza A virus (A/duck/Laos/25/2006(H5N1)) | IC50 | 2.0317 | 3 | 3 |
| Neuraminidase | Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) | IC50 | 0.0002 | 2 | 2 |
| Neuraminidase | Influenza A virus (A/Turkey/651242/2006(H5N1)) | IC50 | 0.1104 | 2 | 2 |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | IC50 | 13.0076 | 82 | 83 |
| Neuraminidase | Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) | Ki | 0.0049 | 1 | 1 |
| Neuraminidase | Influenza A virus (A/duck/Laos/25/2006(H5N1)) | Ki | 0.0011 | 1 | 1 |
| Neuraminidase | Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) | Ki | 0.0001 | 1 | 1 |
| Neuraminidase | Influenza A virus (A/Turkey/651242/2006(H5N1)) | Ki | 0.0079 | 1 | 1 |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | Ki | 0.0005 | 2 | 2 |
| Neuronal acetylcholine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | IC50 | 11.0500 | 1 | 1 |
| Neuronal acetylcholine receptor subunit beta-4 | Rattus norvegicus (Norway rat) | IC50 | 11.0500 | 1 | 1 |
| Neutrophil elastase | Homo sapiens (human) | IC50 | 0.0270 | 1 | 1 |
| NS5 | Zika virus | IC50 | 1.3600 | 1 | 1 |
| Nuclear receptor subfamily 4 group A member 2 | Homo sapiens (human) | IC50 | 13.4000 | 1 | 1 |
| photoreceptor-specific nuclear receptor | Homo sapiens (human) | IC50 | 1.1640 | 1 | 1 |
| polyadenylate-binding protein 1 | Homo sapiens (human) | IC50 | 54.7250 | 2 | 2 |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | Ki | 4.5700 | 1 | 2 |
| Polyphenol oxidase 2 | Agaricus bisporus | IC50 | 4.0000 | 1 | 1 |
| Polyunsaturated fatty acid 5-lipoxygenase | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | IC50 | 2.2580 | 1 | 1 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 | 301.9950 | 1 | 1 |
| Progesterone receptor | Homo sapiens (human) | IC50 | 0.0210 | 1 | 1 |
| Prolyl endopeptidase | Homo sapiens (human) | IC50 | 12.1500 | 2 | 2 |
| Prostacyclin receptor | Homo sapiens (human) | IC50 | 0.0620 | 1 | 1 |
| Prostaglandin E synthase | Homo sapiens (human) | IC50 | 80.0000 | 1 | 1 |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | IC50 | 16.0000 | 1 | 1 |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 1 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | IC50 | 21.7657 | 4 | 5 |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 1 |
| Protein cereblon | Homo sapiens (human) | IC50 | 707.5000 | 1 | 2 |
| Protein cereblon | Homo sapiens (human) | Ki | 212.0000 | 1 | 1 |
| Protein-arginine deiminase type-4 | Homo sapiens (human) | IC50 | 5,250.0000 | 1 | 2 |
| Prothrombin | Homo sapiens (human) | Ki | 0.0020 | 1 | 1 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 | 5.7011 | 8 | 11 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | IC50 | 6.4100 | 1 | 1 |
| Retinoic acid receptor RXR-alpha | Homo sapiens (human) | IC50 | 82.9000 | 1 | 1 |
| Serine/threonine-protein kinase PLK1 | Homo sapiens (human) | IC50 | 3.6100 | 1 | 1 |
| Sialidase | Clostridium perfringens | IC50 | 61.1000 | 1 | 1 |
| Sialidase-1 | Homo sapiens (human) | IC50 | 3,666.6667 | 3 | 3 |
| Sialidase-2 | Homo sapiens (human) | IC50 | 2,333.3333 | 3 | 3 |
| Sialidase-3 | Homo sapiens (human) | IC50 | 5,250.0000 | 4 | 4 |
| Sialidase-4 | Homo sapiens (human) | IC50 | 3,666.6667 | 3 | 3 |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | IC50 | 0.0987 | 3 | 3 |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | Ki | 0.0365 | 2 | 2 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | Ki | 0.3480 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | Ki | 5.0700 | 1 | 1 |
| Sodium channel protein type 1 subunit alpha | Rattus norvegicus (Norway rat) | IC50 | 5.6500 | 2 | 2 |
| Sodium channel protein type 2 subunit alpha | Rattus norvegicus (Norway rat) | IC50 | 5.6500 | 2 | 2 |
| Sodium channel protein type 3 subunit alpha | Rattus norvegicus (Norway rat) | IC50 | 5.6500 | 2 | 2 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | IC50 | 6.4940 | 1 | 2 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | Ki | 5.1595 | 1 | 2 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | IC50 | 4.1582 | 1 | 4 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | Ki | 4.1237 | 1 | 4 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | IC50 | 0.0219 | 1 | 2 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 0.0117 | 1 | 2 |
| Solute carrier family 15 member 1 | Homo sapiens (human) | IC50 | 53,566.6667 | 2 | 3 |
| Solute carrier family 15 member 1 | Homo sapiens (human) | Ki | 790.0000 | 1 | 1 |
| Solute carrier family 15 member 1 | Rattus norvegicus (Norway rat) | Ki | 3,250.0000 | 2 | 2 |
| Solute carrier family 15 member 2 | Rattus norvegicus (Norway rat) | Ki | 230.0000 | 1 | 1 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | IC50 | 70.4375 | 3 | 4 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | IC50 | 2.7000 | 1 | 1 |
| Solute carrier family 22 member 3 | Homo sapiens (human) | IC50 | 74.6000 | 1 | 1 |
| Solute carrier family 22 member 6 | Homo sapiens (human) | IC50 | 13.5000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | IC50 | 11.8200 | 4 | 5 |
| Solute carrier organic anion transporter family member 2A1 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Sphingosine 1-phosphate receptor 1 | Homo sapiens (human) | IC50 | 0.7219 | 2 | 2 |
| Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Sphingosine 1-phosphate receptor 3 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Sphingosine 1-phosphate receptor 4 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Sphingosine 1-phosphate receptor 5 | Homo sapiens (human) | IC50 | 2.1000 | 1 | 1 |
| Sphingosine-1-phosphate lyase 1 | Homo sapiens (human) | IC50 | 34.5000 | 2 | 2 |
| Sphingosine-1-phosphate lyase 1 | Mus musculus (house mouse) | IC50 | 52.4000 | 1 | 1 |
| Steroid 17-alpha-hydroxylase/17,20 lyase | Homo sapiens (human) | IC50 | 0.0175 | 2 | 2 |
| Substance-K receptor | Homo sapiens (human) | IC50 | 28.2240 | 1 | 1 |
| Substance-K receptor | Homo sapiens (human) | Ki | 9.4080 | 1 | 1 |
| Succinyl-diaminopimelate desuccinylase | Haemophilus influenzae Rd KW20 | IC50 | 1,000.0000 | 1 | 1 |
| Thioredoxin reductase | Entamoeba histolytica | Ki | 3.3000 | 1 | 1 |
| Thymidylate kinase | Mycobacterium tuberculosis H37Rv | Ki | 560.0000 | 1 | 1 |
| TPA: protein transporter TIM23 | Saccharomyces cerevisiae S288C | IC50 | 14.9000 | 1 | 1 |
| transactivating tegument protein VP16 [Human herpesvirus 1] | Human alphaherpesvirus 1 (Herpes simplex virus type 1) | IC50 | 4.4260 | 1 | 1 |
| Trypsin-1 | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| Trypsin-2 | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| Trypsin-3 | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | IC50 | 1.2000 | 1 | 1 |
| Tyrosinase | Homo sapiens (human) | IC50 | 8,400.0000 | 1 | 1 |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Tyrosine-protein kinase ABL2 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | IC50 | 2.1460 | 1 | 1 |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | IC50 | 3.7290 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | IC50 | 116.0500 | 2 | 2 |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | IC50 | 116.0500 | 2 | 2 |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | IC50 | 116.0500 | 2 | 2 |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | IC50 | 116.0500 | 2 | 2 |
| X-linked inhibitor of apoptosis | Homo sapiens (human) | IC50 | 100.0000 | 2 | 2 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 26S proteasome regulatory subunit 6B | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | EC50 | 3.4750 | 1 | 1 |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | EC50 | 2.3190 | 1 | 1 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | EC50 | 0.0740 | 1 | 1 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | EC50 | 0.5060 | 1 | 1 |
| 5'-AMP-activated protein kinase catalytic subunit alpha-1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| 5'-AMP-activated protein kinase subunit gamma-1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| 5'-AMP-activated protein kinase subunit gamma-2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| AarF domain-containing protein kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Actin-related protein 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Actin-related protein 3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Activated CDC42 kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Activin receptor type-1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Activin receptor type-1B | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Activin receptor type-2B | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Acyl-CoA dehydrogenase family member 10 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Acyl-CoA dehydrogenase family member 11 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Adenine phosphoribosyltransferase | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Adenosine kinase | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Adenylate kinase 2, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| ADP/ATP translocase 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ADP/ATP translocase 3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Albumin | Homo sapiens (human) | Kd | 44.0000 | 1 | 1 |
| Androgen receptor | Homo sapiens (human) | EC50 | 17.0500 | 1 | 1 |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | EC50 | 2.3806 | 1 | 7 |
| AP2-associated protein kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ATP-dependent 6-phosphofructokinase, platelet type | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ATP-dependent RNA helicase DDX1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ATP-dependent RNA helicase DDX3X | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ATP-dependent RNA helicase DDX42 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Atypical kinase COQ8A, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Aurora kinase A | Homo sapiens (human) | Kd | 0.0490 | 1 | 1 |
| Beta-adrenergic receptor kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| BMP-2-inducible protein kinase | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Bone morphogenetic protein receptor type-1A | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Bone morphogenetic protein receptor type-1B | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Bone morphogenetic protein receptor type-2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Breakpoint cluster region protein | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| calcineurin A1, putative | Candida dubliniensis CD36 | EC50 | 180.0000 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type II subunit delta | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type II subunit gamma | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type IV | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cAMP-dependent protein kinase catalytic subunit alpha | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cAMP-dependent protein kinase catalytic subunit beta | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cAMP-dependent protein kinase catalytic subunit gamma | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cAMP-dependent protein kinase type II-alpha regulatory subunit | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Capsid protein | Hepatitis B virus | EC50 | 5.1850 | 2 | 2 |
| Casein kinase I isoform alpha | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Casein kinase I isoform delta | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Casein kinase I isoform epsilon | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Casein kinase I isoform gamma-1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Casein kinase I isoform gamma-2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Casein kinase I isoform gamma-3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Casein kinase II subunit alpha' | Homo sapiens (human) | Kd | 1.9470 | 1 | 1 |
| cGMP-dependent protein kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE | Paracoccus denitrificans | Kd | 5,000.0000 | 1 | 9 |
| Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE | Paracoccus denitrificans | Kd | 5,000.0000 | 1 | 9 |
| Chromodomain-helicase-DNA-binding protein 4 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Citron Rho-interacting kinase | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Complement C5 | Homo sapiens (human) | Kd | 0.5700 | 1 | 1 |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Cyclin-dependent kinase 12 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Cyclin-dependent kinase 13 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Cyclin-dependent kinase 16 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Cyclin-dependent kinase 17 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Cyclin-dependent kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Cyclin-dependent kinase-like 5 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Cyclin-G-associated kinase | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Cysteine--tRNA ligase, cytoplasmic | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| Cytochrome c1, heme protein, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Cytochrome P450 2C9 | Homo sapiens (human) | EC50 | 0.2300 | 1 | 1 |
| Cytochrome P450 3A4 | Homo sapiens (human) | EC50 | 17.0500 | 1 | 1 |
| dCTP pyrophosphatase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Delta(24)-sterol reductase | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| Deoxycytidine kinase | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Discoidin domain-containing receptor 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| DNA replication licensing factor MCM4 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| DNA topoisomerase 2-alpha | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| DNA topoisomerase 2-beta | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| DNA-(apurinic or apyrimidinic site) endonuclease | Homo sapiens (human) | Kd | 0.0890 | 1 | 1 |
| DnaJ homolog subfamily A member 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Dual specificity mitogen-activated protein kinase kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Dual specificity mitogen-activated protein kinase kinase 5 | Homo sapiens (human) | Kd | 0.0820 | 1 | 1 |
| Dual specificity mitogen-activated protein kinase kinase 6 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Dual specificity protein kinase CLK1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Dual specificity protein kinase CLK2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Dual specificity protein kinase CLK3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Dual specificity testis-specific protein kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Dual specificity testis-specific protein kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) | Kd | 1.6990 | 1 | 1 |
| Dynamin-like 120 kDa protein, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| EKC/KEOPS complex subunit TP53RK | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Electron transfer flavoprotein subunit beta | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Elongation factor Tu, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Ephrin type-A receptor 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Ephrin type-A receptor 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Ephrin type-A receptor 4 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Ephrin type-A receptor 5 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Ephrin type-A receptor 7 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Ephrin type-B receptor 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Ephrin type-B receptor 3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Ephrin type-B receptor 4 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Ephrin type-B receptor 6 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Epidermal growth factor receptor | Homo sapiens (human) | Kd | 1.7340 | 1 | 1 |
| Epithelial discoidin domain-containing receptor 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| Estrogen receptor | Homo sapiens (human) | EC50 | 1.0820 | 2 | 2 |
| Estrogen receptor beta | Homo sapiens (human) | EC50 | 1.0820 | 2 | 2 |
| Eukaryotic translation initiation factor 2-alpha kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Eukaryotic translation initiation factor 5B | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Exosome RNA helicase MTR4 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Ferrochelatase, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Flavin reductase (NADPH) | Homo sapiens (human) | Kd | 0.0704 | 1 | 2 |
| Focal adhesion kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| General transcription and DNA repair factor IIH helicase subunit XPD | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Glucocorticoid receptor | Homo sapiens (human) | EC50 | 0.0004 | 2 | 2 |
| Glucocorticoid receptor | Homo sapiens (human) | Kd | 0.0290 | 1 | 1 |
| Glycine receptor subunit alpha-1 | Homo sapiens (human) | EC50 | 0.3800 | 1 | 1 |
| Glycine--tRNA ligase | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Glycogen phosphorylase, brain form | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Glycogen phosphorylase, liver form | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| GTP-binding nuclear protein Ran | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Guanine nucleotide-binding protein G(i) subunit alpha-2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| heat shock protein 90 | Candida albicans | EC50 | 106.9037 | 3 | 3 |
| Heme oxygenase 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Hepatocyte growth factor receptor | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| High affinity nerve growth factor receptor | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Hsf1 protein | Mus musculus (house mouse) | EC50 | 2.1790 | 2 | 2 |
| Inhibitor of nuclear factor kappa-B kinase subunit epsilon | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Inosine-5'-monophosphate dehydrogenase 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Insulin receptor | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Insulin-like growth factor 1 receptor | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Integrin alpha-L | Homo sapiens (human) | Kd | 12.9000 | 1 | 1 |
| Interleukin-1 receptor-associated kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Interleukin-1 receptor-associated kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Interleukin-1 receptor-associated kinase 4 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Isoleucine--tRNA ligase, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| LIM domain kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| LIM domain kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Long-chain-fatty-acid--CoA ligase 5 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Macrophage-stimulating protein receptor | Homo sapiens (human) | Kd | 1.4160 | 1 | 1 |
| MAP kinase-activated protein kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| MAP kinase-activated protein kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| MAP kinase-activated protein kinase 5 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| MAP/microtubule affinity-regulating kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mas-related G-protein coupled receptor member X2 | Homo sapiens (human) | EC50 | 8.4000 | 2 | 2 |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | Kd | 0.0170 | 1 | 1 |
| Maternal embryonic leucine zipper kinase | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| matrix metalloproteinase 1, partial | Homo sapiens (human) | EC50 | 5.6500 | 1 | 1 |
| Membrane-associated progesterone receptor component 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Midasin | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mineralocorticoid receptor | Homo sapiens (human) | EC50 | 3.0000 | 1 | 1 |
| Misshapen-like kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase 10 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase 11 | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| Mitogen-activated protein kinase 15 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase 7 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase 8 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase 9 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase kinase kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase kinase kinase 11 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase kinase kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase kinase kinase 20 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase kinase kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase kinase kinase 4 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase kinase kinase 5 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase kinase kinase 6 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase kinase kinase kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase kinase kinase kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase kinase kinase kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase kinase kinase kinase 4 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Mitogen-activated protein kinase kinase kinase kinase 5 | Homo sapiens (human) | Kd | 2.2360 | 1 | 1 |
| Mu-type opioid receptor | Homo sapiens (human) | EC50 | 6.1000 | 1 | 1 |
| mu-type opioid receptor isoform MOR-1 | Homo sapiens (human) | EC50 | 92.4680 | 1 | 1 |
| Multifunctional protein ADE2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Myosin light chain kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Myosin light chain kinase, smooth muscle | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Myosin-14 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Non-receptor tyrosine-protein kinase TNK1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| NS5 | Zika virus | EC50 | 15.5100 | 2 | 2 |
| NUAK family SNF1-like kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| Nuclear receptor subfamily 1 group I member 2 | Homo sapiens (human) | EC50 | 1.6020 | 2 | 2 |
| Nuclear receptor subfamily 1 group I member 2 | Rattus norvegicus (Norway rat) | EC50 | 63.1000 | 1 | 1 |
| Nuclear receptor subfamily 4 group A member 2 | Homo sapiens (human) | EC50 | 36.8200 | 5 | 5 |
| Nucleolar GTP-binding protein 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Obg-like ATPase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Peroxisomal acyl-coenzyme A oxidase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Peroxisomal acyl-coenzyme A oxidase 3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | EC50 | 22.6500 | 1 | 1 |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | Kd | 100.0000 | 1 | 1 |
| Phenylalanine--tRNA ligase beta subunit | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Phosphatidylethanolamine-binding protein 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Phospholipid hydroperoxide glutathione peroxidase | Homo sapiens (human) | EC50 | 16.5220 | 2 | 2 |
| Phosphorylase b kinase gamma catalytic chain, liver/testis isoform | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | Kd | 0.0380 | 1 | 1 |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | Kd | 1.3665 | 2 | 2 |
| Probable ATP-dependent RNA helicase DDX6 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Procathepsin L | Homo sapiens (human) | EC50 | 2.3806 | 1 | 7 |
| Prostacyclin receptor | Homo sapiens (human) | EC50 | 0.0060 | 1 | 1 |
| Prostacyclin receptor | Rattus norvegicus (Norway rat) | EC50 | 0.2000 | 1 | 1 |
| Prostaglandin D2 receptor | Homo sapiens (human) | EC50 | 0.1000 | 1 | 1 |
| Protein kinase C alpha type | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Protein kinase C beta type | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Protein kinase C delta type | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Protein kinase C iota type | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Protein kinase C theta type | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Protein-tyrosine kinase 2-beta | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Protein-tyrosine kinase 6 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | Kd | 0.1445 | 2 | 2 |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Putative heat shock protein HSP 90-beta 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Pyridoxal kinase | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Rab-like protein 3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| RAC-alpha serine/threonine-protein kinase | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| RAC-beta serine/threonine-protein kinase | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| RAC-gamma serine/threonine-protein kinase | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Ras-related protein Rab-10 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Ras-related protein Rab-6A | Homo sapiens (human) | Kd | 0.0330 | 1 | 1 |
| Receptor-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | Kd | 1.8500 | 1 | 1 |
| Receptor-interacting serine/threonine-protein kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | Kd | 0.1325 | 2 | 2 |
| recombinase A | Mycobacterium tuberculosis H37Rv | EC50 | 195.1500 | 2 | 2 |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | EC50 | 2.3806 | 1 | 7 |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | EC50 | 2.3806 | 1 | 7 |
| Replicase polyprotein 1ab | Human coronavirus 229E | EC50 | 2.3806 | 1 | 7 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | EC50 | 2.8294 | 4 | 10 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | EC50 | 2.3806 | 1 | 7 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | Kd | 11.9500 | 2 | 2 |
| Retinoic acid receptor alpha | Homo sapiens (human) | EC50 | 0.0630 | 1 | 1 |
| Retinoic acid receptor beta | Homo sapiens (human) | EC50 | 0.0008 | 1 | 1 |
| Retinoic acid receptor gamma | Homo sapiens (human) | EC50 | 0.0400 | 1 | 1 |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | EC50 | 25.0210 | 2 | 2 |
| Rho-associated protein kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Rho-associated protein kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Ribosomal protein S6 kinase alpha-1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Ribosomal protein S6 kinase alpha-3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Ribosomal protein S6 kinase alpha-4 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Ribosomal protein S6 kinase alpha-5 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Ribosomal protein S6 kinase alpha-6 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Ribosomal protein S6 kinase beta-1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| RNA cytidine acetyltransferase | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| RNA-directed RNA polymerase | | EC50 | 0.1454 | 12 | 12 |
| S-adenosylmethionine synthase isoform type-2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Septin-9 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase 10 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase 16 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase 24 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase 26 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase 4 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase ATR | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase Chk1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase D2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase D3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase ICK | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase LATS1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase MARK2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| Serine/threonine-protein kinase MRCK alpha | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase MRCK beta | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase MRCK gamma | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase N1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase N2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase Nek1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase Nek2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase Nek3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase Nek9 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase NLK | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase PAK 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase PAK 4 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase PAK 6 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase PLK4 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase SIK2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase SIK3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase STK11 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase TAO1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase TAO2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase TAO3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase TBK1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase ULK1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase ULK3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| Serine/threonine-protein kinase/endoribonuclease IRE1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Serine/threonine-protein kinase/endoribonuclease IRE2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Sphingosine 1-phosphate receptor 1 | Homo sapiens (human) | EC50 | 3.8349 | 6 | 6 |
| Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) | EC50 | 10.0000 | 1 | 1 |
| Sphingosine 1-phosphate receptor 3 | Homo sapiens (human) | EC50 | 5.6287 | 4 | 4 |
| Sphingosine 1-phosphate receptor 4 | Homo sapiens (human) | EC50 | 5.0002 | 2 | 2 |
| Sphingosine 1-phosphate receptor 5 | Homo sapiens (human) | EC50 | 4.3875 | 3 | 3 |
| Spike glycoprotein | Betacoronavirus England 1 | EC50 | 2.3806 | 1 | 7 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | EC50 | 2.3806 | 1 | 7 |
| STE20-like serine/threonine-protein kinase | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| STE20-related kinase adapter protein alpha | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| streptokinase A precursor | Streptococcus pyogenes M1 GAS | EC50 | 0.4285 | 1 | 2 |
| Structural maintenance of chromosomes protein 1A | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Structural maintenance of chromosomes protein 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Taste receptor type 2 member 16 | Homo sapiens (human) | EC50 | 1,400.0000 | 2 | 2 |
| Taste receptor type 2 member 46 | Homo sapiens (human) | EC50 | 31.0000 | 1 | 1 |
| TGF-beta receptor type-1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| TGF-beta receptor type-2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Thyroid hormone receptor-associated protein 3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| TRAF2 and NCK-interacting protein kinase | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Transmembrane protease serine 2 | Homo sapiens (human) | EC50 | 2.3806 | 1 | 7 |
| Tyrosine--tRNA ligase, cytoplasmic | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Tyrosine-protein kinase ABL2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Tyrosine-protein kinase BTK | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Tyrosine-protein kinase CSK | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Tyrosine-protein kinase Fer | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Tyrosine-protein kinase Fes/Fps | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Tyrosine-protein kinase FRK | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Tyrosine-protein kinase HCK | Homo sapiens (human) | Kd | 2.8860 | 1 | 1 |
| Tyrosine-protein kinase JAK1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Tyrosine-protein kinase Lyn | Homo sapiens (human) | Kd | 3.6330 | 1 | 1 |
| Tyrosine-protein kinase Mer | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Tyrosine-protein kinase SYK | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Tyrosine-protein kinase Tec | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Tyrosine-protein kinase Yes | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| U5 small nuclear ribonucleoprotein 200 kDa helicase | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Uncharacterized protein FLJ45252 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Very long-chain specific acyl-CoA dehydrogenase, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| Wee1-like protein kinase | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |